<?xml version='1.0' encoding='utf-8'?>
<document id="30259783"><sentence text="Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein."><entity charOffset="0-12" id="DDI-PubMed.30259783.s1.e0" text="Posaconazole" /></sentence><sentence text="Drug-drug interactions between digoxin and the triazole antifungal agents, mediated via various cytochrome P450 isozymes, have been described in the literature"><entity charOffset="31-38" id="DDI-PubMed.30259783.s2.e0" text="digoxin" /><entity charOffset="47-55" id="DDI-PubMed.30259783.s2.e1" text="triazole" /><pair ddi="false" e1="DDI-PubMed.30259783.s2.e0" e2="DDI-PubMed.30259783.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30259783.s2.e0" e2="DDI-PubMed.30259783.s2.e1" /></sentence><sentence text=" Posaconazole is not extensively metabolized by these isozymes but is both a p-glycoprotein (P-gp) substrate and inhibitor"><entity charOffset="1-13" id="DDI-PubMed.30259783.s3.e0" text="Posaconazole" /></sentence><sentence text=" To our knowledge, there have been no published cases of clinically significant posaconazole-digoxin drug-drug interactions"><entity charOffset="80-92" id="DDI-PubMed.30259783.s4.e0" text="posaconazole" /></sentence><sentence text=" We report an interaction between posaconazole (300 mg by mouth daily) and digoxin (0"><entity charOffset="34-46" id="DDI-PubMed.30259783.s5.e0" text="posaconazole" /><entity charOffset="75-82" id="DDI-PubMed.30259783.s5.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.30259783.s5.e0" e2="DDI-PubMed.30259783.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30259783.s5.e0" e2="DDI-PubMed.30259783.s5.e1" /></sentence><sentence text="25 mg by mouth daily, Monday through Friday) resulting in atrial fibrillation with slow ventricular response and degenerating into polymorphic ventricular tachycardia" /><sentence text="" /></document>